Logo

ViiV Healthcare's Rukobia (fostemsavir) Receives the US FDA's Approval for HIV in Patients with Limited Treatment Options

Share this

ViiV Healthcare's Rukobia (fostemsavir) Receives the US FDA's Approval for HIV in Patients with Limited Treatment Options

Shots:

  • The approval is based on P-III BRIGHTE study assessing Rukobia (600mg- ER) + OBT in 371 HTE adults living with multidrug-resistant HIV. Participants were enrolled in either a randomized or nonrandomized cohort
  • In the randomized cohort- 60% adults achieved undetectable HIV viral load and clinically meaningful improvements to CD4+ T-cell count @96wks.- HIV-1 RNA <40 copies/mL @24 & 96wks. (53% & 60%); changes in CD4+ cell count (90 & 205 cells/mm3) respectively
  • In the nonrandomized cohort- 37% achieved HIV-1 RNA <40 copies/mL @24 & 96wks.; HIV-1 RNA <200 copies/mL (42% & 39%); mean changes in CD4+ cell count (41 & 119 cells/mm3) respectively. Fostemsavir is a first-in-class HIV-1 attachment inhibitor- currently under EMA’s review with additional submissions to regulatory authorities anticipated in 2020 & 2021

Click here to read full press release/ article | Ref: GSK | Image:  Buisnesswire


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions